| [1] |
Hu X， Luo B， Qiu L，et al.Dezocine has the potential to regulate the clinical and biological features of tumors[J]． Drug Des Devel Ther， 2022(16)：1121-1129.DOI： 10.2147/DDDT.S356863.
|
| [2] |
Liu Y， Li Q， Chen T，et al.Clinical verification of vimentin/EpCAM immunolipid magnetic sorting system in monitoring CTCs in arterial and venous blood of advanced tumor[J]． J Nanobiotechnology， 2021， 19(1)：185.DOI： 10.1186/s12951-021-00929-x.
|
| [3] |
Homma MK， Kiko Y， Hashimoto Y，et al.Intracellular localization of CK2α as a prognostic factor in invasive breast carcinomas[J]． Cancer Sci， 2021， 112(2)：619-628.DOI： 10.1111/cas.14728.
|
| [4] |
López-Ruiz JA， Mieza JA， Zabalza I，et al.Comparison of genomic profiling data with clinical parameters：implications for breast cancer prognosis[J]． Cancers (Basel)， 2022， 14(17)：4197.DOI： 10.3390/cancers14174197.
|
| [5] |
Moding EJ, Nabet BY, Alizadeh AA, et al. Detecting liquid remnants of solid tumors：circulating tumor DNA minimal residual disease[J]． Cancer Discov， 2021， 11(12)：2968-2986.DOI： 10.1158/2159-8290.CD-21-0634.
|
| [6] |
Tarasiuk A， Mackiewicz T， Małecka-Panas E，et al.Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool？[J]． Cancer Biol Ther， 2021， 22(5-6)：347-356.DOI： 10.1080/15384047.2021.1941584.
|
| [7] |
Duffy MJ， Lamerz R， Haglund C，et al.Tumor markers in colorectal cancer，gastric cancer and gastrointestinal stromal cancers：european group on tumor markers 2014 guidelines update[J]． Int J Cancer， 2014， 134(11)：2513-2522.DOI： 10.1002/ijc.28384.
|
| [8] |
Heitzer E， Haque IS， Roberts C，et al.Current and future perspectives of liquid biopsies in genomics-driven oncology[J]． Nat Rev Genet， 2019， 20(2)：71-88.DOI： 10.1038/s41576-018-0071-5.
|
| [9] |
Schraa SJ， van Rooijen KL， Koopman M，et al.Cell-free circulating (tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer：a systematic review[J]． Cancers (Basel)， 2022， 14(9)：2218.DOI： 10.3390/cancers14092218.
|
| [10] |
Wang R， Zhao A， Cao N，et al.The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer：a meta-analysis[J]． Int J Colorectal Dis， 2020， 35(8)：1463-1475.DOI： 10.1007/s00384-020-03667-y.
|
| [11] |
Chen Y， Mo S， Wu M，et al.Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis[J]． Int J Colorectal Dis， 2022， 37(5)：1021-1027.DOI： 10.1007/s00384-022-04144-4.
|
| [12] |
Henriksen TV， Tarazona N， Frydendahl A，et al.Circulating tumor DNA in stage Ⅲ colorectal cancer，beyond minimal residual disease detection，toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences[J]． Clin Cancer Res， 2022， 28(3)：507-517.DOI： 10.1158/1078-0432.CCR-21-2404.
|
| [13] |
Fu R， Huang J， Tian X，et al.Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer：results from a multicenter study[J]． Mol Oncol， 2023， 17(5)：825-838.DOI： 10.1002/1878-0261.13387.
|
| [14] |
Raunkilde L， Hansen TF， Andersen RF，et al.NPY Gene methylation in circulating tumor DNA as an early biomarker for treatment effect in metastatic colorectal cancer[J]． Cancers (Basel)， 2022， 14(18)：4459.DOI： 10.3390/cancers14184459.
|
| [15] |
Malla M， Loree JM， Kasi PM，et al.Using circulating tumor DNA in colorectal cancer：current and evolving practices[J]． J Clin Oncol， 2022， 40(24)：2846-2857.DOI： 10.1200/JCO.21.02615.
|
| [16] |
Azzi G， Tavallai M， Aushev VN, et al. Using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma[J]． ONCOLOGIST， 2023， 28 (3)：220-229.DOI： 10.1093/oncolo/oyac249.
|
| [17] |
Coombes RC， Page K， Salari R，et al.Personalized detection of circulating tumor dna antedates breast cancer metastatic recurrence[J]． Clin Cancer Res， 2019， 25(14)：4255-4263.DOI： 10.1158/1078-0432.CCR-18-3663.
|
| [18] |
Hua X， Zhou H， Wu HC，et al.Tumor detection by analysis of both symmetric- and hemi-methylation of plasma cell-free DNA[J]． Nat Commun， 2024， 15(1)：6113.DOI： 10.1038/s41467-024-50471-1.
|
| [19] |
Cristiano S， Leal A， Phallen J，et al.Genome-wide cell-free DNA fragmentation in patients with cancer[J]． Nature， 2019， 570(7761)：385-389.DOI： 10.1038/s41586-019-1272-6.
|
| [20] |
Li Y， Jiang G， Wu W，et al.Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease[J]． EBioMedicine， 2023(91)：104553.DOI： 10.1016/j.ebiom.2023.104553.
|
| [21] |
Tie J， Cohen J， Wang YX，et al.The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC)[J]． J CLIN ONCOL， 2017， 35 (15_suppl)：3521-3521.DOI： 10.1200/jco.2017.35.15_suppl.3521.
|
| [22] |
Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling[J]． Cancer Discov， 2017， 7(12)：1394-1403.DOI： 10.1158/2159-8290.CD-17-0716.
|
| [23] |
Zhong R， Gao R， Fu W，et al.Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer：a meta-analysis[J]． BMC Med， 2023， 21(1)：180.DOI： 10.1186/s12916-023-02849-z.
|
| [24] |
Magbanua M， Swigart LB， Wu HT，et al.Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival[J]． Ann Oncol， 2021， 32(2)：229-239.DOI： 10.1016/j.annonc.2020.11.007.
|
| [25] |
Birkenkamp-Demtröder K， Christensen E， Nordentoft I，et al.Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis[J]． Eur Urol， 2018， 73(4)：535-540.DOI： 10.1016/j.eururo.2017.09.011.
|
| [26] |
Phallen J， Sausen M， Adleff V，et al.Direct detection of early-stage cancers using circulating tumor DNA[J]． Sci Transl Med， 2017， 9(403)：eaan2415.DOI： 10.1126/scitranslmed.aan2415.
|
| [27] |
Wang Y， Li L， Cohen JD，et al.Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer[J]． JAMA Oncol， 2019， 5(8)：1118-1123.DOI： 10.1001/jamaoncol.2019.0512.
|
| [28] |
Taniguchi H， Nakamura Y， Kotani D，et al.CIRCULATE-Japan：circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer[J]． Cancer Sci， 2021， 112(7)：2915-2920.DOI： 10.1111/cas.14926.
|
| [29] |
Tie J， Cohen JD， Lahouel K，et al.Circulating tumor dna analysis guiding adjuvant therapy in stage Ⅱ colon cancer[J]． N Engl J Med， 2022， 386(24)：2261-2272.DOI： 10.1056/NEJMoa2200075.
|
| [30] |
Tsuboi M， Herbst RS， John T，et al.Overall survival with osimertinib in resected EGFR-mutated NSCLC[J]． N Engl J Med， 2023， 389(2)：137-147.DOI： 10.1056/NEJMoa2304594.
|
| [31] |
Herbst RS， John T， Grohé C，et al.Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage ⅠB-ⅢA non-small-cell lung cancer[J]． Nat Med， 2025， 31(6)：1958-1968.DOI： 10.1038/s41591-025-03577-y.
|
| [32] |
Felip E， Altorki N， Zhou C，et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB-ⅢA non-small-cell lung cancer (IMpower010)：a randomised，multicentre，open-label，phase 3 trial[J]． Lancet， 2021， 398(10308)：1344-1357.DOI： 10.1016/S0140-6736(21)02098-5.
|
| [33] |
Sugimoto A， Matsumoto S， Udagawa H，et al.A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)[J]． Clin Cancer Res， 2023， 29(8)：1506-1514.DOI： 10.1158/1078-0432.CCR-22-1749.
|
| [34] |
Stadler JC， Belloum Y， Deitert B，et al.Current and future clinical applications of ctDNA in Immuno-Oncology[J]． Cancer Res， 2022， 82(3)：349-358.DOI： 10.1158/0008-5472.CAN-21-1718.
|
| [35] |
Powles T， Assaf ZJ， Davarpanah N，et al.ctDNA guiding adjuvant immunotherapy in urothelial carcinoma[J]． Nature， 2021， 595(7867)：432-437.DOI： 10.1038/s41586-021-03642-9.
|
| [36] |
Turner NC， Swift C， Jenkins B，et al.Results of the c-TRAK TN trial：a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer[J]． Ann Oncol， 2023， 34(2)：200-211.DOI： 10.1016/j.annonc.2022.11.005.
|
| [37] |
Lee JH， Long GV， Boyd S，et al.Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma[J]． Ann Oncol， 2017， 28(5)：1130-1136.DOI： 10.1093/annonc/mdx026.
|
| [38] |
Chan WY, Lee JH, Stewart A, et al. Circulating tumour DNA dynamics predict recurrence in stage Ⅲ melanoma patients receiving neoadjuvant immunotherapy[J]． J Exp Clin Cancer Res， 2024， 43(1)：238.DOI： 10.1186/s13046-024-03153-1.
|
| [39] |
Loeffler C， Bando H， Sainath S，et al.HIBRID：histology-based risk-stratification with deep learning and ctDNA in colorectal cancer[J]． Nat Commun， 2025， 16(1)：7561.DOI： 10.1038/s41467-025-62910-8.
|
| [40] |
Volinsky-Fremond S, Horeweg N, Andani S, et al. Prediction of recurrence risk in endometrial cancer with multimodal deep learning[J]． Nat Med， 2024， 30(7)：1962-1973.DOI： 10.1038/s41591-024-02993-w.
|
| [41] |
Dhaliwal A， Zandu M， Khurana S，et al.Anti CD19 CAR-T cell therapy can clear minimal residual disease in bone marrow of patients with relapsed or refractory B cell non-hodgkin′s lymphomas[J]． BLOOD， 2022， 140 (Supple 1)：12760-12761.DOI： 10.1182/blood-2022-170620.
|
| [42] |
Kasi A， Diaz F， Al-Rajabi RMT，et al.Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 ＋/- PD-1 inhibitor，balstilimab：a randomized phase II study (TESLA)[J]． J Clin Oncol， 2023， 41 (16_suppl)：TPS4205-TPS4205.DOI： 10.1200/jco.2023.41.16_suppl.tps4205.
|